HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has maintained a Buy rating on Enanta Pharmaceuticals (NASDAQ:ENTA) but has reduced the price target from $30 to $28.

November 21, 2023 | 11:53 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Enanta Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., but the price target is lowered from $30 to $28.
While the maintenance of a Buy rating is positive, the reduction in price target could signal a tempered expectation of future performance, which may have a neutral to slightly negative impact on the stock price in the short term. The confidence in the analysis is high due to the direct mention of the company and the specific nature of the price target change.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100